3   Reconsolidation blockade with propranolol as a novel

4   treatment for chronic low-back pain: a double-blind

5   randomized placebo-controlled feasibility study

Alexia Coulombe-Leveque[1], Sylvie Lafrenaye[2], Alain Brunet[3], Serge Marchand[2], Guillaume

Léonard[1]

1. Centre de recherche sur le vieillissement, Université de Sherbrooke, Sherbrooke,

Québec, Canada

2. Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Université de

Sherbrooke, Sherbrooke, Québec, Canada

3. University of the Sunshine Coast, Sunshine Coast, Queensland, Australia

Correspondence: Guillaume Léonard

Centre de recherche sur le vieillissement

1036 Rue Belvédère S, Sherbrooke, QC, Canada J1H 2J7

Email: guillaume.leonard2@usherbrooke.ca

Abstract:

Purpose: Nociplastic pain is often characterized by maladaptive plasticity in the nervous system similar to that observed in patients with post-traumatic stress disorder (PTSD). The aim of this study was to investigate whether reconsolidation therapy, a treatment for PTSD consisting in reactivating (through trauma narrative) the synapses encoding the excessive threat response and blocking their reconsolidation using propranolol, is feasible in patients with nociplastic low-back pain.

Patients and methods: Design: triple-blind, placebo-controlled feasibility study.

Population: 24 adults with chronic (>6 months) nociplastic low-back pain with no comorbid PTSD or contra-indication to propranolol.

Intervention: Pain education (10 short videos) and 6 weekly sessions of reconsolidation therapy with propranolol (n=12) or placebo (n=12) administered orally 1h pre-reactivation).

Outcome measures:

Feasibility: recruitment rates, adverse events (frequency/severity).

Effect of intervention: Brain Pain Inventory (BPI) and other self-reported pain questionnaires, 4 weeks post-intervention.

Results: Sixty-six patients were screened over 6 months; 24 participants were enrolled; 2 dropped out. Adverse events were mild and infrequent (asymptomatic decrease in heart rate (n=4), headache and nausea (n=1). No clinically meaningful difference was observed between the two groups on the pain questionnaires. However, we noted prevalent catastrophic/kinesiophobic discourse during the sessions, and the reactivation methods appeared to have been suboptimal for the population.

Conclusion: Reconsolidation therapy is a feasible intervention for chronic pain. Preliminary results suggest no effect on pain symptoms. Additional studies are warranted to assess the adequacy of reactivation procedures (proper reactivation being required to trigger reconsolidation), and to investigate whether the absence of negative pain beliefs might be a prerequisite (unmet in this study) for the success of the intervention.

Keywords: Reconsolidation Therapy, nociplastic pain, post-traumatic stress disorder, amygdala

Introduction

Chronic nociplastic pain is characterized by plastic changes within the central nervous system [1],

notably by a shift in pain representation within the brain from the somatosensory areas towards

the limbic system [2,3].

The amygdala, a key component of the limbic system involved in threat learning, has emerged as

a particular region of interest in the physiopathology of nociplastic pain. Evidence suggests that

the amygdala plays a pronociceptive role in the context of chronic pain [4–9], and morphological as

well as functional alterations have been observed in the amygdala of patients with nociplastic

pain [9–17]. In parallel, animal studies have shown that chemogenetic activation of the amygdala

can induce or heighten pain behaviours, while its silencing inhibits or prevents them (see [6,11] for

reviews).

These changes in the limbic system are reminiscent of those observed in patients with post-

traumatic stress disorder (PTSD) [9,18–20], who exhibit increased amygdala reactivity after excessive

threat learning [21–23]. A new treatment for PTSD was developed in the 2010s, which specifically

aims to reverse these plastic changes in the amygdala: reconsolidation therapy (RT) [24,25]. RT is

based on synaptic reconsolidation, a process rediscovered by Susan Sara and Jean

Przybyslawski in the late '90s and popularized by Karim Nader in 2000 [26–28]. Its principles are

rooted in the concept that a consolidated synaptic trace, when reactivated under certain

conditions, requires *re*-consolidation; during this period, the synapse becomes temporarily

unstable and malleable, and certain molecules can be administered to interfere with its

reconsolidation, which results in the long-term weakening of the synaptic connection [29,30]. Such

agents include protein-synthesis inhibitors and, for reconsolidation blockade in the amygdala, the

lipophilic beta-blocker propranolol [26,31,32]. RT for the treatment of PTSD consists of two elements:

i) a 'reactivation', wherein patients are asked, for instance, to write an autobiographical script of

their traumatic experience (so as to cause the underlying synaptic connections to undergo

reconsolidation); and ii) administration of propranolol (to disrupt the reconsolidation of the

reactivated synaptic traces in the amygdala, thereby weakening them and normalizing the

pathologically heightened threat response) [25,33].

Given its aim to reverse maladaptive amygdala plasticity – and the evidence implicating such

plasticity in nociplastic pain – RT represents a promising therapeutic candidate warranting

investigation. Yet, to date and to the best of our knowledge, no clinical study has investigated the

feasibility and/or potential benefits of RT in patients with chronic pain.

The primary objective of this study was to assess the feasibility and acceptability of a modified RT

intervention (6 weekly sessions of RT with placebo or propranolol) delivered to adults with chronic

nociplastic low back pain. The secondary objective was to gather preliminary data on the effect of

the intervention on patient-reported pain symptoms (physical function, pain intensity, emotional

function).

Material and methods

Study Design

We conducted a double-blind, randomized, placebo-controlled feasibility study. A feasibility

design was selected because reconsolidation therapy had never been studied as a possible

treatment for chronic pain and requires the off-label use of propranolol, which raised important

considerations in terms of recruitment (rates and selection criteria) and safety. The research

protocol was approved by the local institutional ethics board (Comité d'éthique de la recherche du

CIUSSS de l'Estrie-CHUS) and a non-objection letter was obtained from Health Canada, Division

5 on August 27th, 2021. The study was registered in Clinical Trials (NCT05085782) on September

27th, 2021. The study took place at the Research Center of the CIUSSS-de-l'Estrie-CHUS

(Sherbrooke, Québec, Canada). Signed informed consent was obtained for all participants. There

were no deviations from the research protocol during the trial.

Monitoring

An independent study monitor conducted a full review of the study documentation (eg, operations manual, delegation log, equipment log, medication handling and storage procedures, contingency plan, ethical training certificates, etc.), as well as two data handling quality assessments.

Setting

The study took place at the Research Center of the CIUSSS-de-l'Estrie-CHUS (Sherbrooke, Québec, Canada) from February to October 2022.

Participants

This study was conducted in adults with chronic nociplastic low-back pain. (The study protocol was written before the term "nociplastic pain" gained widespread recognition and acceptance – as such, it uses the term "central sensitization" as operationalized by Nijs [34]. However, seeing as this operationalization is consistent with the concept of "nociplastic pain" as defined by the IASP [1], this manuscript will use the term "nociplastic pain" to reflect the latest science.)

Inclusion criteria were: 1) age 18 to 65 years old; 2) ability to understand spoken and written French; 3) low-back pain present for more than 6 months; 4) average daily pain intensity greater than 3/10 (verbal numeric scale); and 5) presence of nociplastic pain. This last criterion was assessed using the algorithm developed by Nijs et al. [34], which states that the presence of central sensitization can be suspected if neuropathic pain is unable to explain the clinical presentation, and if patients present 1) pain of disproportionate intensity relative to the nature and severity of the lesion ; and 2a) diffuse or neurologically implausible pain distribution ; or 2b) score of 40 or higher on the Central Sensitization Inventory (CSI), part A [35]. These were assessed via a full standardized clinical evaluation (performed by ACL, physiotherapist).

Exclusion criteria were: 1) contraindication to propranolol; 2) contraindication to reconsolidation therapy [33] (eg, acute suicidal ideation; substance abuse); 3) comorbid PTSD; 4) recent (<3 years) lumbar surgery; 5) recent (<3 months) change in treatment; 6) involvement in a lawsuit related to the pain condition.

Recruitment

Participants were recruited between February and August 2022 through adverts on social media and posters in medical clinics, physiotherapy clinics, and at the local hospital (convenience sampling). Eligibility was assessed through a preliminary phone screening and an in-person admissibility visit.

Intervention

The intervention consisted of pain education and 6 weekly sessions of reconsolidation therapy with propranolol or a placebo.

Pain Education

Prior to the first intervention session, participants watched 10 educational videos on pain neuroscience (2–4 minutes each). These videos were produced for the study by an experienced physiotherapist currently practicing with a chronic pain population (ACL), in collaboration with two patient-partners. Pain education was included in both groups as it is a recommended treatment for chronic pain treatment [36], thereby making the intervention multimodal and ensuring that the experimental treatment was not compared to a placebo alone.

Reconsolidation Therapy

The experimental intervention included 6 weekly sessions of reconsolidation therapy [25,33], which combines a brief (10-15 mins) reactivation procedure with administration of propranolol (or a placebo). The reactivation procedure, which for PTSD revolves around a narrative script of the traumatic event, was modified for the chronic pain population by a transdisciplinary team including experts in chronic pain, experts in reconsolidation therapy, and a patient partner. Three distinct reactivation themes were developed (to increase mismatch between sessions [37]) and used sequentially during each of the six intervention sessions (Theme A: Sessions 1 and 4; Theme B: Sessions 2 and 5; and so on).

Theme A, dubbed "Painful Event", followed the PTSD treatment protocol most closely: patients

were asked to verbally recount (out loud) their *most salient* episode of low back pain, in the first

person, present tense, and to describe contextual and environment cues (eg sounds, odours, and

other physical sensations associated with the event).

Theme B, dubbed "Nightmare Scenario", was inspired by reconsolidation blockade as applied for

the treatment of phobias [38,39] and from studies on Picture Imagination Tasks [40]: participants were

instructed to visualize a 'nightmarish scenario' related to their pain (eg having to perform

particularly painful tasks or movements).

Theme C, dubbed "Negative Emotions", was based on the well-established role of the amygdala

in negative emotions, and the similarly well-established link between negative emotions and pain

[6,9,12,13,41,42]. Participants were asked to describe and try to feel the emotions they typically felt

during a painful episode (low back-related).

Propranolol

This study used short-acting propranolol (Teva-Canada) as the reconsolidation-blocking agent.

The propranolol was encapsulated to look identical to the placebo (corn starch) by Gentès &

Bolduc Pharmacists Canada. Dosage was the same as is used for PTSD [25,33]: 40, 60 or 80 mg

per session (based on height and self-reported biological sex, see Table 1). As per the PTSD

treatment protocol, propranolol (or placebo) capsules were ingested at the beginning of each

experimental session (along with a small snack to facilitate absorption [43]) one hour prior to the

reactivation procedure, so that the reactivation theoretically coincided with the peak plasma

concentration of propranolol [44].

Timeline of visits

V0. After an initial phone screening, prospective participants attended an admissibility visit (V0) at

the research center. During this visit, a standardized clinical assessment was conducted by ACL

to confirm eligibility, and participants completed the baseline pain questionnaires (see *outcome*

measures).

V1-V6. Participants attended six weekly sessions of RT (V1 to V6).

At the beginning of each session, participants ingested the propranolol (or placebo) capsules and

then engaged in a calming activity for 1h, such as reading or using a screen, while waiting for the

medication to take effect [44]. Heart rate and blood pressure were measured before medication

intake and again 30 and 60 minutes later. After the 60-min vitals monitoring, the therapist

performed a brief (10-15 mins) reactivation procedure (theme A for V1 & V4; theme B for V2 &

V5; theme C for V3 & V6).

Follow-up (FUP). Participants completed the post-intervention pain questionnaires online (from

home) four weeks after the final intervention session (V6).

Intervention Quality Monitoring

180   The study coordinator (ACL) completed the official Reconsolidation Therapy training course (2.5

181   days), and trained the other therapist (MT) accordingly. To ensure proper implementation of the

182   protocol, an external expert in reconsolidation therapy listened to approximately 10% of the

183   reactivation sessions (giving priority to earlier sessions) and provided feedback.

Outcome measures

Feasibility

Feasibility measures were selected based on the recommendations of Thabane et al. [45], and

include: 1) recruitment (rates and reasons for ineligibility); 2) completion of the intervention

(adherence to treatment schedule, attrition, and dropouts); 3) adverse events (type, frequency,

severity, attribution, expected/unexpected); 4) blinding success (perceived group allocation).

Adverse events (AEs) were recorded throughout the study. For the purpose of assessing the

safety of propranolol in our population, a HR lower than 55 bpm and/or a decrease of 30% in HR

or BP was considered an AE. The severity of each AE was graded on a scale from 1 to 5 as per

the Common Terminology Criteria for Adverse Events (CTCAE), wherein an AE of grade 1 is

asymptomatic or mild, and an AE of grade 2 requires treatment [46].

Acceptability

The acceptability of the intervention was assessed as per the recommendations of Sekhon et al. [47]. The five constructs assessed were: 1) burden; 2) ethics; 3) intervention consistency; 4) intervention effectiveness; and 5) self-efficacy. Each construct was assessed before and after the intervention (at V0 and FUP) with a numerical rating scale (NRS).

Effect of the intervention

The outcome measures used to assess the effect of the intervention were selected based on the IMMPACT (Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials) recommendations for clinical trials in chronic pain populations [48,49]. The variables assessed were 1) the impact of pain on physical function, assessed using the Brief Pain Inventory – Short Form (BPI) [50]; 2) pain severity, also assessed using the BPI; 3) emotional function, assessed using the Profile of Mood States (POMS) [51]; 4) symptoms of central sensitization (a population-specific instrument), assessed using the CSI part A; and 5) perception of change assessed using the Patient Global Impression of Change (PGIC) [52]. Each questionnaire was completed during the admissibility visit (V0) and at follow-up (FUP), except for the PGIC which was only completed at FUP. Additionally, the BPI was completed during each intervention session, such that partial data was available for participants lost to follow-up (however, it should be noted that reconsolidation blockade affects long-term memory only, and not short-term memory [31]; as such, RT is not expected to decrease pain during sessions).

Sample size

The protocol aimed to recruit 24 participants. As the primary objective of the study was to assess the feasibility of the intervention rather than obtain statistically significant results, no sample size calculation was performed. The sample size of 24 was selected based on the recommendations of Julious et al. [53], according to which 12 participants per group is adequate for this type of study.

Allocation and blinding

Group allocation was performed using minimization [54,55], which was completed by an independent research professional using the free and open-source software MinimPy2 [56]. The randomization index was minimal (99%) and the minimization factors were CSI score, BPI score, symptom duration, gender, and age. The participants and the therapists administering the sessions and overseeing the questionnaire completion were blinded to the group allocation.

Statistical analysis

The feasibility indicators, such as enrollment rates and adverse events, are presented in the form of flowcharts and descriptive tables. Considering the small sample size and feasibility design, the emphasis was similarly placed on descriptive analyses for measures of acceptability and intervention effect. No interim analyses were planned or conducted.

Results

Sample

As planned, 24 adults with low back pain (12 per group) were recruited to participate in the study. Their average age was 42 ± 12 y.o. in the control group and 49 ± 13 y.o. in the experimental group. Both groups had seven women and five men. Additional sociodemographic information can be found in Table 2.

Feasibility

Recruitment, adherence & retention

Sixty-six potential candidates were screened over 6 months, 35 of which completed the admissibility visit (Figure 1). Of the 24 participants enrolled in the study, 22 completed all 6 intervention visits. One participant in the control group (male, in his 30s) withdrew after the 4th

visit because of emotional discomfort during the reactivation sessions, but completed the follow-

up. Another participant (female, in her 60s) was excluded after the 4th visit because she started a

new treatment at a pain clinic; her results related to feasibility and acceptability were analyzed as

planned, but her pain scores at follow-up were not considered (analyses were conducted using

her initial scores).

Of the 22 participants who completed all six intervention visits, 13 completed them in the planned

6-week period; 7 participants postponed one session by a week; and 2 participants postponed

two sessions so the intervention took place over 8 weeks. Most postponed sessions were due to

illness or holidays.

In the experimental group, 3 participants believed they received the propranolol and 5 believed

they received the placebo. In the control group, 1 participant believed they received the

propranolol and 6 believed they received the placebo. The remaining participants reported no

suspicion either way.

Safety & adverse events

Effect of propranolol on HR and BP

The variations in heart rate and blood pressure from baseline to 60 minutes after medication are

summarized in Figure 2. Heart rate decreased by an average of 11 bpm in the experimental

group, compared to 3 bpm in the control group (asymptomatic in all participants). No clinically

meaningful changes in blood pressure were observed in either group (average change <4

mmHg).

Adverse events

AEs classified as related or possibly related to the intervention are listed in Table 3. In the control

group, one participant experienced nightmares following sessions 3 and 4. In the experimental

group, four participants experienced a significant (but asymptomatic) decrease in heart rate, and

one participant experienced fatigue, nausea, and a headache in the evening following her second

visit, but self-managed with acetaminophen and had no symptoms after her other visits.

Acceptability

Five aspects of acceptability (burden, ethicality, self-efficacy, coherence, and perceived efficacy) were assessed before and after the intervention using 11-pts NRSs (0 = strongly disagree; 10 = strongly agree). The average scores for both groups were generally favorable (see Figure 3), although for both groups, the burden, coherence and perceived efficacy of the intervention tended to be rated less favorably at follow-up.

Effect of the intervention

The effect of treatment on symptoms was evaluated using the BPI-intensity, BPI-function, POMS, CSI, and PGIC. Figure 4 shows the change in individual scores for each questionnaire, with negative values indicating a decrease in symptoms (ie, an improvement). Approximately half of the participants in both groups experienced a clinically significant improvement in physical function ($\geq$ 1/10); other outcomes remained stable on average and were similar across the two groups, suggesting no superior effect of the experimental intervention over the placebo intervention (Fig 4).

Incidental findings

Two unforeseen findings related to the adequacy of the intervention emerged during the study. The first concerned participants' understanding of their pain condition, and the second their response to the reactivation procedures.

Pain conceptualization

No formal measure was used to assess participant's understanding of the mechanism underlying their low back pain. However, throughout the study, the language used by participants to describe their condition suggested that they conceptualized their pain as stemming from a musculoskeletal lesion, and as being an adequate indicator of tissue damage. For instance, most participants described their pain using language suggesting a strong belief that their pain originated from a musculoskeletal lesion – citing elements such as osteoarthritis, a 'weak spine', displaced

292   vertebrae, etc. Such explicit beliefs about tissue damage and risk of injury may have been a

293   major confounding factor in this study, as discussed below.

Reactivation procedures

Different issues were also noted with each of the 3 reactivation "themes".

Theme A (worst pain episode)

This theme, wherein participants were asked to describe their most painful episode, followed the

PTSD protocol as closely as possible – including instructions to describe the environment and all

sensory experiences associated with the event. Participants could easily identify and describe

their most painful event, they often appeared unsettled when asked to describe the environment,

the sounds and smells associated with the event. Most participants reported that these prompts

were jarring; not only could they seldom remember those details, having to focus on these

(perceived) irrelevant details also 'pulled them out' of the immersion.

Theme B ("worst nightmare")

For this theme participants had to make up and picture a 'nightmare scenario' related to their pain

– in other words, to picture doing an activity they expected would cause pain. However, several

participants unexpectedly described a scenario where pain ended up not being the primary

concern (eg, waking up on a particularly bad day, lying in bed unable to move because of

excruciating, debilitating pain – then hearing their child being struck by a car and being unable to

provide assistance because of the severity of their pain). For others, the implausibility of

performing or carrying on with a pain-inducing activity (instead of resting, stopping, or modifying

the activity) appeared to prevent full immersion.

Theme C (negative emotions)

This theme aimed to reactivate negative emotions associated with pain. Based on our patient-

partner pre-tests, we expected that patients would describe emotions such as distress, anxiety,

and pain-related fear. However, the majority of participants spontaneously described emotions

related to the consequences of the pain (eg, guilt over not being able to fulfill their role as parents

318 or spouses; fear that they might end up in a wheelchair; frustration with the healthcare system),

319 rather than related to the pain itself.

320 Discussion

321 The objective of this study was to assess the feasibility and acceptability of reconsolidation

322 therapy as a treatment for chronic nociplastic low back pain, and to gather preliminary data on the

323 effect of the intervention on patient-reported pain symptoms.

324 *Feasibility*

325 The intervention appears safe, with only mild and infrequent adverse events in the experimental

326 group. These results are unsurprising given propranolol's favorable safety profile [44]; however,

327 seeing as the medication was used off-label, and for the first time with people suffering from low

328 back pain, documenting its safety was crucial. There were relatively few dropouts (n = 1 in each

329 group), and the participants generally adhered to the treatment schedule: the majority of

330 participants completed their 6 visits over the planned 6 weeks, and only 2 participants required

331 the maximum allowed time of 8 weeks to complete their 6 visits. These results suggest that the

332 intervention is feasible with this population.

333 *Acceptability*

334 The results regarding acceptability were favorable, with the notable exception of perceived

335 efficacy, which was rated lower by both groups following the intervention. This may have been

336 due to the lack of improvement experienced by most participants. However, these generally high

337 acceptability scores should be regarded cautiously, as they were likely inflated by a sampling bias

338 – the prospective participants who judged the study unacceptable after seeing the recruitment

339 posters presumably chose not to contact our research team, such that their unfavorable opinions

340 remain undocumented. Moreover, acceptability measures have advanced considerably since the

341 experimental protocol was developed. The design of future acceptability studies should take

342 advantage of these new tools.

Pain education

Some of the improvements observed in certain participants may have been due to pain education. However, the absence of clinically significant improvement in the control group – and, indirectly, the persistence of beliefs equating pain to tissue damage, despite educational content on nociplastic pain – suggests that the videos did not have a clinically meaningful impact, on average. Future studies could allocate additional resources to pain education, for example by adding prompts and quizzes throughout the video (to improve engagement and monitor adherence), or by having the education delivered in person by a healthcare professional.

Effect of the intervention

Our findings suggest that, in this particular form and application, RT had no impact on pain symptoms, as we did not observe a clinically meaningful pattern suggesting that the experimental group experienced a greater reduction in symptoms compared to the control group. However, this does not constitute robust proof that RT cannot be an effective treatment for chronic nociplastic pain. Indeed, as discussed above, the activation procedures used may have failed to fully reactivate the target synapses – which would mean there was no reconsolidation for propranolol to interfere with. It is also possible that the success of RT depends on participants not holding a strong belief that their pain indicates tissue damage – a prerequisite that was not met in the present study. Therefore, it is still possible that another version of RT, properly accounting for these two potential confounding factors, could benefit patients suffering from chronic pain (see below).

Incidental findings – adequacy of the intervention

Pain beliefs & conceptualization

The language used by participants suggests that they conceptualized their pain as arising from (and signalling) tissue damage to their lumbar spine. In other words, they appeared to hold *explicit beliefs* that their spine's physical integrity was compromised. This could represent a

fundamental (and not previously considered) difference between patients with chronic low-back

pain and those with PTSD, the latter likely being more aware that their fear reactions are

excessive and disproportionate to the actual threat level. The explicit belief that pain stems from

physical injury could have affected the efficacy of the intervention. Indeed, reconsolidation

blockade with propranolol does not target (explicit) declarative or episodic memory, but rather

targets (implicit) associations encoded in the amygdala [57,58]. Moreover, research on the nocebo

effect has shown that the mere belief that something is harmful or causes pain can lead to pain,

even in the absence of actual damage or threat of damage [59–61]. As such, holding a belief that

pain reflects physical injury could be sufficient to trigger and maintain the chronic nociplastic pain

state – regardless of any possible weakening effect of reconsolidation blockade on implicit

associations in the amygdala. In other words, it is possible that reconsolidation blockade can only

benefit patients who recognize that their pain is maladaptive and arises from a dysregulation in

the nervous system – a prerequisite that was unmet in the present study. To clarify this matter,

future studies are needed that either provide more pain education, have inclusion criteria related

to pain beliefs, or formally assess pain beliefs to determine whether they are indeed a

prerequisite for RT success.

Reactivation procedures

As outlined in the results, despite the adaptations implemented, the reactivation protocols

employed in the present study appear to have been suboptimal for our population. This could

have hindered the effect of the intervention, as reactivation is a fundamental aspect of RT.

Indeed, only synapses that have been specifically reactivated return to a labile state and are

susceptible to reconsolidation blockade, and a number of (often subtle) boundary conditions must

be met for reactivation to be effective [62–64]. For instance, while the feelings of guilt and

helplessness evoked in many participants during Theme C are valid and understandable, they

may not be as closely linked to the amygdala as fear of injury or pain (the intended target for

Theme C). However, now that the shortcomings of the current reactivation procedures have been

documented, future studies should attempt to further depart from the PTSD protocol. Specifically,

they should modify the reactivation procedures to tailor them more specifically to the pain

population, for example by focusing on daily painful experiences or mental imagery of painful

activities.

Additional considerations for future studies

Despite the plausibility of its mechanism of action, RT remains relatively unknown outside of

psychotraumatology and is mostly absent from the pain literature (with the notable exception of

an elegant pre-clinical study by Bonin and De Koninck targeting spinal nociceptive circuits [65]).

Now that the general feasibility of RT has been established and that the safety of off-label

propranolol in patients with chronic pain has been documented, a next step might be to conduct

imaging studies to confirm the mechanistic plausibility of the intervention. Indeed, the intervention

postulates that reactivation procedures activate the amygdala (necessary to trigger synaptic

reconsolidation), but this has never been validated and will need to be confirmed. Such

mechanistic studies should also assess different reactivation methods (verbal descriptions *vs*

visual imagery; focusing on specific pain episodes *vs* typically painful activities, etc.) to identify

those that most reliably activate the amygdala in patients with chronic pain. The mechanism of

action of RT also postulates that propranolol acts specifically by blocking reconsolidation in the

amygdala. This assumption is largely based on preclinical studies showing similar effects whether

propranolol is administered systemically [27] or directly into the amygdala [31], with similar outcomes

observed using other reconsolidation-blocking agent such as anisomycine [26]. However, this

mechanism will need to be validated in pain as well.

The present study was designed before criteria for nociplastic pain were established criteria [66],

and future studies should obviously follow the latest recommendations when establishing their

selection criteria. RT might also be studied in other populations of nociplastic pain, such as

women with vestibulodynia or patients with comorbid nociplastic pain and PTSD.

Conclusion

This was a pioneering study – the first, to our knowledge, to study reconsolidation therapy as a possible treatment for chronic pain. It provides the very first data regarding the use of this intervention in that population. Notably, our results support the safety of the intervention, an important first step in any investigation involving the off-label use of medication. Moreover, while results relating to the effect of the intervention failed to show any benefit of RT in this specific form, two major possible confounding factors were identified – both of which can be addressed by reworking the intervention protocol. As such, our findings provide a strong foundation for future studies, reflecting the iterative nature of research and highlights the importance of running pilot studies before embarking in large randomized trials.

Acknowledgments

The authors would like to thank Virginie Carrier, the study monitor, for her outstanding competence and continued support. They would also like to thank Marilyn Tousignant for her role as therapist; Michelle Lonergan for her role as reconsolidation expert; Jonathan Landry for his contribution to the production of the pain education videos; and Mélanie Morin and Martine Bordeleau for their technical advising during study design.

Disclosure

The first author is supported by a Fellowship from the Canadian Institutes of Health Research Fellowship; the study was funded by the Quebec Pain Research Network (Fonds de recherche du Québec – Santé); and GL received salary support by the Fonds de recherche du Québec – Santé (Senior Clinical Research Scholar).
AB teaches reconsolidation therapy for the treatment of PTSD. There are no other conflicts of interest to declare.
The data used in the present study are available from the authors upon request.

References

1. Raja SN, Carr DB, Cohen M, et al. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. *PAIN*. 2020;161(9):1976. doi:10.1097/j.pain.0000000000001939

2. Baliki MN, Chialvo DR, Geha PY, et al. Chronic pain and the emotional brain: specific brain activity associated with spontaneous fluctuations of intensity of chronic back pain. *J Neurosci*. 2006;26(47):12165-12173. doi:10.1523/JNEUROSCI.3576-06.2006

3. Hashmi JA, Baliki MN, Huang L, et al. Shape shifting pain: chronification of back pain shifts brain representation from nociceptive to emotional circuits. *Brain*. 2013;136(Pt 9):2751-2768. doi:10.1093/brain/awt211

4. Kulkarni B, Bentley DE, Elliott R, et al. Arthritic pain is processed in brain areas concerned with emotions and fear. *Arthritis & Rheumatism*. 2007;56(4):1345-1354. doi:10.1002/art.22460

5. Lewis GN, Parker RS, Sharma S, Rice DA, McNair PJ. Structural Brain Alterations Before and After Total Knee Arthroplasty: A Longitudinal Assessment. *Pain Medicine*. 2018;19(11):2166-2176. doi:10.1093/pm/pny108

6. Neugebauer V. 15. Amygdala pain mechanisms. *Handb Exp Pharmacol*. 2015;227:261-284. doi:10.1007/978-3-662-46450-2_13

7. Neugebauer V, Li W, Bird GC, Han JS. The Amygdala and Persistent Pain. *Neuroscientist*. 2004;10(3):221-234. doi:10.1177/1073858403261077

8. Neugebauer V, Galhardo V, Maione S, Mackey SC. Forebrain pain mechanisms. *Brain Res Rev*. 2009;60(1):226-242. doi:10.1016/j.brainresrev.2008.12.014

9. Veinante P, Yalcin I, Barrot M. The amygdala between sensation and affect: a role in pain. *J Mol Psychiatry*. 2013;1(1). doi:10.1186/2049-9256-1-9

10. Seno MDJ, Assis DV, Gouveia F, et al. The critical role of amygdala subnuclei in nociceptive and depressive-like behaviors in peripheral neuropathy. *Sci Rep*. 2018;8(1):13608. doi:10.1038/s41598-018-31962-w

11. Thompson JM, Neugebauer V. Amygdala Plasticity and Pain. *Pain Research and Management*. 2017;2017:e8296501. doi:10.1155/2017/8296501

12. Simons LE, Moulton EA, Linnman C, Carpino E, Becerra L, Borsook D. The human amygdala

and pain: evidence from neuroimaging. *Hum Brain Mapp*. 2014;35(2):527-538.

doi:10.1002/hbm.22199

13. Hsiao FJ, Chen WT, Ko YC, et al. Neuromagnetic Amygdala Response to Pain-Related Fear

as a Brain Signature of Fibromyalgia. *Pain & Therapy*. 2020;9(2):765-781.

doi:10.1007/s40122-020-00206-z

14. Neugebauer V. 15. Amygdala pain mechanisms. *Handb Exp Pharmacol*. 2015;227:261-284.

doi:10.1007/978-3-662-46450-2_13

15. Vachon-Presseau E, Tétreault P, Petre B, et al. Corticolimbic anatomical characteristics

predetermine risk for chronic pain. *Brain*. 2016;139(7):1958-1970. doi:10.1093/brain/aww100

16. Llorca-Torralba M, Suárez-Pereira I, Bravo L, et al. Chemogenetic Silencing of the Locus

Coeruleus–Basolateral Amygdala Pathway Abolishes Pain-Induced Anxiety and Enhanced

Aversive Learning in Rats. *Biological Psychiatry*. 2019;85(12):1021-1035.

doi:10.1016/j.biopsych.2019.02.018

17. McCarberg B, Peppin J. Pain Pathways and Nervous System Plasticity: Learning and

Memory in Pain. *Pain Medicine*. 2019;20(12):2421-2437. doi:10.1093/pm/pnz017

18. Asmundson GJ, Coons MJ, Taylor S, Katz J. PTSD and the Experience of Pain: Research

and Clinical Implications of Shared Vulnerability and Mutual Maintenance Models. *Can J*

Psychiatry. 2002;47(10):930-937. doi:10.1177/070674370204701004

19. Sandkühler J. Learning and memory in pain pathways. *PAIN*. 2000;88(2):113.

doi:10.1016/S0304-3959(00)00424-3

20. Timmers I, Quaedflieg CWEM, Hsu C, Heathcote LC, Rovnaghi CR, Simons LE. The

interaction between stress and chronic pain through the lens of threat learning. *Neurosci*

Biobehav Rev. 2019;107:641-655. doi:10.1016/j.neubiorev.2019.10.007

21. Harnett NG, Goodman AM, Knight DC. PTSD-related neuroimaging abnormalities in brain

function, structure, and biochemistry. *Experimental Neurology*. 2020;330:113331.

doi:10.1016/j.expneurol.2020.113331

22. Rauch SL, Shin LM, Phelps EA. Neurocircuitry Models of Posttraumatic Stress Disorder and

Extinction: Human Neuroimaging Research—Past, Present, and Future. *Biological*

Psychiatry. 2006;60(4):376-382. doi:10.1016/j.biopsych.2006.06.004

23. Gilboa A, Shalev AY, Laor L, et al. Functional connectivity of the prefrontal cortex and the
amygdala in posttraumatic stress disorder. *Biological Psychiatry*. 2004;55(3):263-272.
doi:10.1016/j.biopsych.2003.08.004

24. Brunet A, Orr SP, Tremblay J, Robertson K, Nader K, Pitman RK. Effect of post-retrieval
propranolol on psychophysiologic responding during subsequent script-driven traumatic
imagery in post-traumatic stress disorder. *J Psychiatr Res*. 2008;42(6):503-506.
doi:10.1016/j.jpsychires.2007.05.006

25. Brunet A, Saumier D, Liu A, Streiner DL, Tremblay J, Pitman RK. Reduction of PTSD
Symptoms With Pre-Reactivation Propranolol Therapy: A Randomized Controlled Trial. *AJP*.
2018;175(5):427-433. doi:10.1176/appi.ajp.2017.17050481

26. Nader K, Schafe GE, Le Doux JE. Fear memories require protein synthesis in the amygdala
for reconsolidation after retrieval. *Nature*. 2000;406(6797):722-726. doi:10.1038/35021052

27. Przybyslawski J, Roullet P, Sara SJ. Attenuation of emotional and nonemotional memories
after their reactivation: role of beta adrenergic receptors. *J Neurosci*. 1999;19(15):6623-6628.

28. Przybyslawski J, Sara SJ. Reconsolidation of memory after its reactivation. *Behav Brain Res*.
1997;84(1-2):241-246.

29. Agren T. Human reconsolidation: A reactivation and update. *Brain Research Bulletin*.
2014;105:70-82. doi:10.1016/j.brainresbull.2013.12.010

30. Elsey, Van Ast VA, Kindt M. Human memory reconsolidation: A guiding framework and
critical review of the evidence. *Psychological Bulletin*. 2018;144(8):797-848.
doi:10.1037/bul0000152

31. D☐biec J, LeDoux JE. Noradrenergic Signaling in the Amygdala Contributes to the
Reconsolidation of Fear Memory. *Annals of the New York Academy of Sciences*.
2006;1071(1):521-524. doi:10.1196/annals.1364.056

32. Schwabe L, Nader K, Wolf OT, Beaudry T, Pruessner JC. Neural signature of reconsolidation
impairments by propranolol in humans. *Biological Psychiatry*. 2012;71(4):380-386.
doi:10.1016/j.biopsych.2011.10.028

33. Brunet A, Ayrolles A, Gambotti L, et al. Paris MEM: a study protocol for an effectiveness and
efficiency trial on the treatment of traumatic stress in France after the 2015–16 terrorist
attacks. *BMC Psychiatry*. 2019;19(1):351. doi:10.1186/s12888-019-2283-4

34. Nijs J, Apeldoorn A, Hallegraeff H, et al. Low back pain: guidelines for the clinical
classification of predominant neuropathic, nociceptive, or central sensitization pain. *Pain*
Physician. 2015;18(3):E333-346.

35. Mayer TG, Neblett R, Cohen H, et al. The Development and Psychometric Validation of the
Central Sensitization Inventory (CSI). *Pain Pract.* 2012;12(4):276-285. doi:10.1111/j.1533-
2500.2011.00493.x

36. Kim H, Lee S. Effects of pain neuroscience education on kinesiophobia in patients with
chronic pain: a systematic review and meta-analysis. *Physical Therapy Rehabilitation*
Science. 2020;9(4):309-317. doi:10.14474/ptrs.2020.9.4.309

37. Cahill EN, Wood MA, Everitt BJ, Milton AL. The role of prediction error and memory
destabilization in extinction of cued-fear within the reconsolidation window.
Neuropsychopharmacology⬚: official publication of the American College of
Neuropsychopharmacology. 2019;44(10):1762-1768. doi:10.1038/s41386-018-0299-y

38. Elsey JWB, Kindt M. Placebo and Non-specific Effects in Reconsolidation-Based Treatment
for Arachnophobia. *Frontiers in psychiatry.* 2021;12:775770. doi:10.3389/fpsyt.2021.775770

39. Peters J, Filmer AM, Van Doorn JB, Metselaar V, Visser RM, Kindt M. A Reconsolidation
Intervention for Spider Phobia: Re-Encountering the Feared Situation After Treatment is
Crucial to Initiate Cognitive Changes in Fear. *Biological Psychiatry.* 2023;93(9):S135.
doi:10.1016/j.biopsych.2023.02.342

40. Taylor AM, Harris AD, Varnava A, et al. A Functional Magnetic Resonance Imaging Study to
Investigate the Utility of a Picture Imagination Task in Investigating Neural Responses in
Patients with Chronic Musculoskeletal Pain to Daily Physical Activity Photographs. *PLoS*
One. 2015;10(10):e0141133. doi:10.1371/journal.pone.0141133

41. Missig G. *Amygdala PACAP as a Mediator of the Emotional Components of Pain.* ProQuest
Information & Learning; 2016.

42. Strobel C, Hunt S, Sullivan R, Sun J, Sah P. Emotional regulation of pain: the role of
noradrenaline in the amygdala. *Science China Life Sciences.* 2014;57(4):384-390.
doi:10.1007/s11427-014-4638-x

43. Melander A. Influence of food on the bioavailability of drugs. *Clin Pharmacokinet.*
1978;3(5):337-351.

44. Teva Canada Ltd. Product Monograph. PrTEVA-Propranolol. (Propranolol Hydrochloride).
Published online 2011. https://pdf.hres.ca/dpd_pm/00014382.PDF

45. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. *BMC*
Medical Research Methodology. 2010;10(1). doi:10.1186/1471-2288-10-1

46. U.S. Department of Health and Human Services, National Institutes of Health, National
Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), V5.0.
Published online 2017.
https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm

47. Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of
reviews and development of a theoretical framework. *BMC Health Serv Res*. 2017;17(1):88.
doi:10.1186/s12913-017-2031-8

48. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials:
IMMPACT recommendations. *Pain*. 2005;113(1):9-19. doi:10.1016/j.pain.2004.09.012

49. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the Clinical Importance of Treatment
Outcomes in Chronic Pain Clinical Trials: IMMPACT Recommendations. *The Journal of Pain*.
2008;9(2):105-121. doi:10.1016/j.jpain.2007.09.005

50. Cleeland CS, Ryan KM. The brief pain inventory. *Pain Research Group*. Published online
1991:143-147.

51. Cayrou S, Dickès P, Dolbeault S. Version française du profile of mood states (POMS-f).
Journal de Thérapie Comportementale et Cognitive. 2003;13(2):83-88.

52. Guy W. *ECDEU Assessment Manual for Psychopharmacology*. US Department of Health,
Education, and Welfare, Public Health Service …; 1976.

53. Julious SA. Sample size of 12 per group rule of thumb for a pilot study. *Pharmaceutical*
Statistics. 2005;4(4):287-291. doi:https://doi.org/10.1002/pst.185

54. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting
randomized trials: explanation and elaboration. *Annals of internal medicine*. 2001;134(8):663-
694.

55. Altman DG, Bland JM. Treatment allocation by minimisation. *BMJ*. 2005;330(7495):843.
doi:10.1136/bmj.330.7495.843

56. Saghaei M, Saghaei S. Implementation of an open-source customizable minimization
program for allocation of patients to parallel groups in clinical trials. *J Biomed Sci Eng*.
2011;4(734):10-4236.

57. Lonergan MH, Olivera-Figueroa LA, Pitman RK, Brunet A. Propranolol's effects on the
consolidation and reconsolidation of long-term emotional memory in healthy participants: a
meta-analysis. *J Psychiatry Neurosci*. 2013;38(4):222-231. doi:10.1503/jpn.120111

58. Pigeon S, Lonergan M, Rotondo O, Pitman RK, Brunet A. Impairing memory reconsolidation
with propranolol in healthy and clinical samples: a meta-analysis. *Journal of Psychiatry and*
Neuroscience. 2022;47(2):E109-E122. doi:10.1503/jpn.210057

59. Colloca L, Barsky AJ. Placebo and Nocebo Effects. *New England Journal of Medicine*.
2020;382(6):554-561. doi:10.1056/NEJMra1907805

60. Geuter S, Büchel C. Facilitation of Pain in the Human Spinal Cord by Nocebo Treatment. *J*
Neurosci. 2013;33(34):13784-13790. doi:10.1523/JNEUROSCI.2191-13.2013

61. Rossettini G, Campaci F, Bialosky J, Huysmans E, Vase L, Carlino E. The Biology of Placebo
and Nocebo Effects on Experimental and Chronic Pain: State of the Art. *Journal of Clinical*
Medicine. 2023;12(12):4113. doi:10.3390/jcm12124113

62. Bui UTD, Milton AL. Making Leaps and Hitting Boundaries in Reconsolidation: Overcoming
Boundary Conditions to Increase Clinical Translatability of Reconsolidation-based Therapies.
Neuroscience. 2023;519:198-206. doi:10.1016/j.neuroscience.2023.03.013

63. Chen L, Yan H, Wang Y, et al. The Mechanisms and Boundary Conditions of Drug Memory
Reconsolidation. *Frontiers in neuroscience*. 2021;15:717956. doi:10.3389/fnins.2021.717956

64. Ferrara NC, Kwapis JL, Trask S. Memory retrieval, reconsolidation, and extinction: Exploring
the boundary conditions of post-conditioning cue exposure. *Frontiers in synaptic*
neuroscience. 2023;15:1146665. doi:10.3389/fnsyn.2023.1146665

65. Bonin RP, De Koninck Y. A spinal analog of memory reconsolidation enables reversal of
hyperalgesia. *Nature Neuroscience*. 2014;17(8):1043-1045. doi:10.1038/nn.3758

66. Kosek E, Clauw D, Nijs J, et al. Chronic nociplastic pain affecting the musculoskeletal
system: clinical criteria and grading system. *PAIN*. 2021;162(11):2629.
doi:10.1097/j.pain.0000000000002324

Table 1 – Propranolol Dosage

	Women	Men
40 mg	<165 cm	<155 cm
60 mg	165-185 cm	155-175 cm
80 mg	>185 cm	>175 cm

622 *Table 1 shows the dosage of propranolol (or placebo) based on height and (self-reported)*

623 *biological sex.*

 Table 2 – Sociodemographic Information

	Ctrl (n=12)	Exp (n=12)
Age (avg ± sd)	42 ± 12	49 ± 13
Pain duration	18 ± 16	21 ± 12
Nb women	7	7
Occupation		
Student	3	1
Employed	5	8
Retired	1	3
Unfit for work	2	0
On leave	1	0
Ethnicity		
Caucasian	11	12
Latino	1	0

627   *Table 2 shows the socio-demographic characteristics of the sample.*

628   **Abbreviations:** *Exp, Experimental; Ctrl, Control*

629 # Table 3 – Adverse events

	Description	Group	Severity (1-5)	Expected/ unexpected	Session
L.008	Nightmares	Ctrl	1	Unexpected	V3, V4
L.007	Headache, nausea, fatigue	Exp	1	Unexpected	V2
L.059	↓ HR - asymptomatic (88 to 61 bpm)	Exp	1	Expected	V1
L.048	↓ HR - asymptomatic (106 to 67 bpm)	Exp	1	Expected	V6
L.019	↓ HR - asymptomatic (78 to 53 bpm; 66 to 52 bpm)	Exp	1	Expected	V5, V6
L.038	↓ HR - asymptomatic (105 to 71 bpm; 108 to 71 bpm; 110 to 75 bpm)	Exp	1	Expected	V1, V2, V5

Adverse events observed throughout the study. Severity is classified as per the Common

Terminology Criteria for Adverse Events (CTCAE).

Abbreviations*: Exp, Experimental; Ctrl, Control; HR, Heart rate; bpm, Beats per minute*

Fig 1 – Recruitment flowchart.

Fig 1 shows the recruitment flowchart for the study.

Fig 2 – Variations in heart rate and blood pressure.

Fig 2 shows the average change in heart rate (a) and blood pressure (systolic (b); diastolic (c))

from baseline to 60 mins post-medication.

Abbreviations: *Exp, Experimental; Ctrl, Control; HR, Heart rate; bpm, Beats per minute; SBP,*

systolic blood pressure; DBP, diastolic blood pressure

Figure 3 – Acceptability scores.

Fig 3 shows the average acceptability ratings for each of the five constructs. Ratings were

obtained before the intervention (V0) and at follow-up (FUP – 4 weeks post-intervention), for both

groups.

Abbreviations: *Exp, Experimental; Ctrl, Control; FUP, follow-up*

Fig 4 – Effect of the intervention.

4a

4b

4c

4d

4e

Fig 4 shows the individual changes observed in each participant for each outcome measure (Brief

Pain Inventory – Function (a); Brief Pain Inventory – Intensity (b); Central Sensitization Inventory

(c); Profile of Mood States (d); Patient Global Impression of Change (e). Negative scores

represent reductions in symptoms, ie, improvements (∆ = FUP – V0). The green line indicates the

threshold for clinical significance for each instrument.

Abbreviations: *Exp, Experimental; Ctrl, Control; FUP, follow-up; Fct, function; Int, Intensity; CSI,*

Central Sensitization Inventory; POMS, Profile of Mood States; PGIC, Patient Global Impression

of Change